The global CAR T-cell therapy market is positioned for substantial growth, with the market size expected to reach approximately US$5.8 billion by 2025 and forecasted to surge to US$24 billion by 2032. This growth is anticipated at a compound annual growth rate (CAGR) of 25% during the forecast period of 2025 to 2032. The market’s expansion is primarily driven by the increasing prevalence of hematological malignancies, advancements in gene-editing technologies, and expanding indications in oncology, alongside supportive regulatory frameworks.
CAR T-cell therapy, a form of immunotherapy, represents a significant breakthrough in the treatment of cancers, particularly hematological malignancies, and is gradually finding wider clinical application. This expanding therapeutic potential, along with rising healthcare investments, is fueling the robust growth environment of CAR T-cell therapy.
Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/28264
Key Industry Highlights
The CAR T-cell therapy market’s growth trajectory is shaped by several key industry highlights:
Leading & Fastest-growing Disease Indications: Lymphoma is predicted to hold the largest market share, approximately 40%, in 2025. Meanwhile, multiple myeloma is set to be the fastest-growing segment, experiencing significant growth from 2025 to 2032.
Leading & Fastest-growing Drug Types: Yescarta, developed by Gilead Sciences, will continue to lead the market, with an estimated market share of 35% in 2025. However, Abecma, another CAR T-cell therapy, is expected to grow the fastest, with the highest CAGR during the forecast period.
Dominant Region: North America is anticipated to dominate the CAR T-cell therapy market, accounting for approximately 45% of the global share in 2025. This is driven by the advanced innovation ecosystem in the U.S. and its regulatory environment.
Fastest-growing Regional Market: Asia Pacific is expected to be the fastest-growing regional market, propelled by rapid advancements in healthcare infrastructure and regulatory modernization across several countries.
Market Dynamics: Growth Drivers, Restraints, and Opportunities
Drivers
Rising Cancer Prevalence: The increasing incidence of hematologic cancers such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, and multiple myeloma is one of the primary drivers of the CAR T-cell therapy market. According to the International Agency for Research on Cancer, approximately 553,389 cases of NHL were reported globally in 2022, driving the demand for innovative therapies.
Advancements in CAR T-cell Technology: Innovations such as improved antigen targeting, safety switches, and advancements in manufacturing processes are increasing the efficacy and safety of CAR T-cell therapies, thus expanding their clinical adoption.
Regulatory Support: Regulatory bodies such as the U.S. FDA and the European Medicines Agency (EMA) have established accelerated approval pathways for CAR T-cell therapies, encouraging faster development and market entry of these treatments.
Restraints
High Treatment Costs: The cost of CAR T-cell therapy is a major barrier to widespread adoption. With treatment costs exceeding US$400,000 per patient, reimbursement issues and economic constraints pose significant challenges, especially in emerging economies where healthcare infrastructure may be insufficient to support such high-cost therapies.
Complex Manufacturing Processes: CAR T-cell therapies involve highly specialized autologous manufacturing, where a patient’s own cells are harvested, modified, and re-infused. This process is time-consuming and requires specialized facilities, which limits the scalability of production.
Supply Chain Bottlenecks: The specialized nature of CAR T-cell therapy production, coupled with the limited number of manufacturing sites and the complex logistics of delivering personalized treatment, can lead to supply chain bottlenecks. This may result in delays and increased operational costs.
Opportunities
Technological Innovations: The integration of gene-editing tools like CRISPR and advancements in allogeneic (off-the-shelf) CAR T-cell therapies are poised to significantly reduce production costs and time. These innovations will also allow for broader scalability, making CAR T-cell therapies more accessible to a larger patient population.
Emerging Markets: The rapidly expanding healthcare infrastructure in Asia Pacific, Latin America, and the Middle East presents significant opportunities for market players. Countries like China and India, with their rising cancer incidence rates, are expected to drive demand for advanced therapies.
Category-wise Analysis
Drug Type Insights
Yescarta: Gilead Sciences’ Yescarta is the leading CAR T-cell therapy, with an estimated market share of 35% in 2025. Its early approval in the U.S. and Europe, coupled with its clinical efficacy in treating relapsed/refractory large B-cell lymphoma (DLBCL) and other hematologic cancers, solidifies its position as the market leader.
Abecma: The highest CAGR during the forecast period is expected from Abecma, a therapy designed to treat multiple myeloma. As the first FDA-approved CAR T-cell therapy for this indication, Abecma’s clinical success, combined with increasing prevalence and the expanding label for treatment, is driving rapid uptake.
Target Antigen Insights
CD19-targeted Therapies: The CD19-targeted CAR T-cell therapy segment will dominate the market with a 55% revenue share in 2025. These therapies are highly effective against B-cell malignancies such as NHL and acute lymphoblastic leukemia, providing long-lasting remissions for relapsed or refractory patients.
BCMA-targeted Therapies: BCMA-targeted CAR T-cell therapies, such as Abecma and Carvykti, are poised to experience rapid growth due to the increasing incidence of multiple myeloma. These therapies show high efficacy in patients with relapsed/refractory multiple myeloma, making them a key growth driver in the CAR T-cell market.
Disease Indication
Lymphoma: Lymphoma is expected to account for 40% of the market share in 2025, driven by the high prevalence of aggressive forms such as DLBCL. Durable remissions demonstrated in clinical trials and expanding healthcare coverage are further boosting demand for CAR T-cell therapies in this segment.
Multiple Myeloma: Multiple myeloma is the fastest-growing segment, with increasing incidence rates and improved survival outcomes due to new therapies. Projections indicate that the market for multiple myeloma treatments will reach nearly US$42 billion by 2032, opening new avenues for CAR T-cell therapies.
Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/28264
Regional Insights
North America
North America is projected to hold approximately 45% of the global market share in 2025. The region benefits from an advanced healthcare infrastructure, high disease awareness, and favorable reimbursement policies for oncology treatments. The U.S., in particular, serves as a hub for CAR T-cell therapy development, driven by strong venture capital funding and the regulatory support of the FDA. Key industry players, including Gilead Sciences and Novartis, are headquartered in the U.S., further fueling the region’s dominance.
Europe
Europe is expected to capture about 30% of the global CAR T-cell therapy market by 2025. Regulatory harmonization across countries, coupled with government-backed healthcare reforms, is facilitating the rapid adoption of CAR T-cell therapies. Germany, the U.K., and France are expected to lead the market, supported by well-established reimbursement frameworks and a strong focus on cell-based therapies.
Asia Pacific
Asia Pacific is anticipated to become the fastest-growing market, driven by rising cancer prevalence, expanding healthcare infrastructure, and increasing governmental healthcare spending. China, Japan, and India are key growth markets, with improving regulatory frameworks that aim to expedite access to innovative therapies.
Competitive Landscape
The CAR T-cell therapy market is moderately consolidated, with major players such as Gilead Sciences (via Kite Pharma), Novartis, and Bristol-Myers Squibb dominating the market. These companies hold an estimated 70% of the market share as of 2025. Competition is fierce, with smaller biopharma firms contributing to innovation and focusing on niche segments. Strategic partnerships, acquisitions, and mergers are expected to continue as key players seek technological synergies and geographic expansions.
Key Industry Developments
In October 2025, the ZUMA-24 study showed that outpatient Yescarta treatment for DLBCL is both safe and feasible, reducing hospital stays and improving patient quality of life.
In March 2025, Cellogen Therapeutics launched the first indigenously developed Bi-Specific 3rd Gen CAR T-cell therapy in India, reducing treatment costs by over 90% through local production.
Key Players
Gilead Sciences, Inc.
Novartis AG
Bristol-Myers Squibb Company
Legend Biotech Corporation
Cellectis S.A.
Autolus Therapeutics Plc
Adaptimmune Therapeutics Plc
Mustang Bio, Inc.
Bellicum Pharmaceuticals, Inc.
MaxCyte, Inc.
Tessa Therapeutics
Caribou Biosciences, Inc.
Takeda Pharmaceutical Company Limited
Sorrento Therapeutics, Inc.
Poseida Therapeutics, Inc.
Future Outlook
The CAR T-cell therapy market is poised for rapid expansion, driven by technological advancements, increasing disease prevalence, and strong regulatory support. As manufacturing and supply chain bottlenecks are addressed and innovative models for payment and reimbursement are adopted, the market will become more accessible globally. The future holds tremendous potential for CAR T-cell therapies to address a broader range of cancers, potentially transforming the landscape of oncology treatments. The Asia Pacific region, in particular, offers a high-value opportunity for business expansion, with increasing healthcare infrastructure and rising demand for advanced therapies.
